About CD-Venture
CD-Venture is a venture capital firm founded in 2003. It is primarily based out of Heidelberg, Germany. As of Aug 2024, CD-Venture has invested in 12 companies. It primarily invests in Series B round in Germany based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series D round of Leon-nanodrugs Overall, CD-Venture portfolio has seen 3 IPOs and 4 acquisitions including key companies like Exosome Diagnostics, Stocard and Noxxon Pharma. A lot of funds co-invest with CD-Venture, with names like Yabeo sharing a substantial percentage of its portfolio. CD-Venture has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 3 more
Portfolio IPOs
CD-Venture's List of Top Investments
CD-Venture has a portfolio of 12 companies. Their most notable investments are in Curetis and Leon-nanodrugs.Their portfolio spans across Germany and United States. They have invested in Life Sciences, High Tech, Enterprise Applications and 6 other sectors, across stages such as Series A, Series B and 3 more. Here is the list of top investments by CD-Venture:
1. Wellth
Wellth provides an AI and cloud-based technology to healthcare payors and ACOs to produce cost-saving behavior changes in their members through science-based incentive plans. It engages and encourages customers to manage their diseases appropriately and take preventive actions. Users can log in to the platform and create a targeted incentive plan, set their goals, and allow verification of their results. Rewards are given to users who show positive change and maintain their health.
Key facts about Wellth
- Founded Year: 2014
- Location: Brooklyn (United States)
- Stage: Series C
- Total Funding till date: $73.1M
- Employee Count: 144 as on May 31, 2026
- Investors: New York Life Ventures, Tigerlabs and 34 Others
- Latest Funding Round: Series C, Aug 21, 2025, $*****
- Highlight: Editors' Pick
Developer of blood-based cancer molecular diagnostics for patient stratification and disease monitoring. The company's ExoDx Prostate test extract exosomes that contain disease-specific nucleic acids shed by solid tumors into bodily fluids and detect key genes and gene mutations associated with prostate cancer.
Key facts about Exosome Diagnostics
- Founded Year: 2008
- Location: Boston (United States)
- Stage: Acquired
- Total Funding till date: $119M
- Employee Count: 59 as on Mar 31, 2026
- Investors: b2venture, CD-Venture and 7 Others
- Latest Funding Round: Series C, Jul 05, 2017, $*****
- Highlight: Acquired
3. Stocard
Stocard provides an app-based platform for reward payments. It enables users to stores loyalty cards in the wallet. It offers reward points at each purchase using the stored loyalty card. The reward points can be used at partner merchants. It also enables businesses to accept reward points as payment. App is available on iOS and Android devices.
Key facts about Stocard
- Founded Year: 2011
- Location: Mannheim (Germany)
- Stage: Acquired
- Total Funding till date: $25.4M
- Employee Count: 12 as on May 31, 2026
- Investors: Rocketship, HTGF and 8 Others
- Latest Funding Round: Series B, Jun 05, 2018, $*****
- Highlight: Acquired
4. Wirelane
Provider of hardware, software, and services for electric vehicle charging. The company offers a range of charging stations and management software. These products support various applications, including hotels, municipalities, and commercial properties. Services include planning, installation, and maintenance of charging infrastructure.
Key facts about Wirelane
Developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics. The company’s systems support process development and GMP production of nanoparticles. They engineer technology that aims to redefine precision and performance in nanoparticle production. The company empowers partners to accelerate the development of next-generation therapeutics.
Key facts about Leon-nanodrugs
- Founded Year: 2011
- Location: Munich (Germany)
- Stage: Series D
- Total Funding till date: $20.3M
- Employee Count: 19 as on May 31, 2026
- Investors: CD-Venture, LifeCare Partners and 7 Others
- Latest Funding Round: Series D, Aug 06, 2024, $*****
- Highlight: Editors' Pick
CD-Venture's Year-on-Year Investment Trends
CD-Venture has invested in 12 companies over the last 16 years, with an average of 0 new investment annually in the last 10 years. Its most recent first time investment was in Wirelane and most recent follow-on round was in Leon-nanodrugs.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 1 | 1 |
2023 | 1 | 1 | 2 |
2022 | 0 | 0 | 0 |
2021 | 0 | 0 | 0 |
2020 | 1 | 1 | 2 |
2019 | 0 | 0 | 0 |
2018 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
CD-Venture's Investments by Stage
CD-Venture has made 4 investments in Series A stage with an average round size of $11.1M, 3 investments in Series B stage with an average round size of $23.2M, 3 investments in Series C stage with an average round size of $12.4M, 1 investment in Seed stage with an average round size of $850K and 1 investment in Series D stage with an average round size of $2.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 4 |
Series B | 3 |
Series C | 3 |
Seed | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
CD-Venture's Investments by Sector
CD-Venture has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, Sustainability Tech and Auto Tech. Notably, it has invested in 12 Tech companies, 11 Enterprise (B2B) companies, 6 Software companies and at least 3 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 9 |
High Tech | 5 |
Enterprise Applications | 3 |
Sustainability Tech | 2 |
Auto Tech | 1 |
Others | 6 |
Note: We have considered here, only first round of investments
CD-Venture's Investments by Geography
CD-Venture has made most investments in Germany (7), followed by United States where it has made 5 investments.Country | No. of Investments |
|---|---|
Germany | 7 |
United States | 5 |
Note: We have considered here, only first round of investments
CD-Venture's recent investments
CD-Venture has not made any investment in 2026 so far.Here are the most recent investments by CD-Venture:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 06, 2024 | Germany | Series D | 1883 | [+3] | |
Aug 22, 2023 | Germany | Series B | 4769 | - | |
Mar 31, 2023 | United States | Series B | 3212 | [+5] | |
Apr 21, 2020 | Germany | Series C | 1325 | ||
Apr 16, 2020 | Germany | Series B | 3133 |
IPOs and Publicly Listed companies in CD-Venture's Portfolio
3 of CD-Venture's portfolio companies have become public. Noxxon Pharma got listed on the Euronext Exchange (Euronext), in Sep 2016 at marketcap of $49.1M and Flex Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $285M.Here are CD-Venture's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 30, 2016 | Oct 13, 2010 | Series D | 9289 | |
Jan 30, 2015 | Sep 08, 2014 | Series B | 6841 | |
- | Sep 21, 2010 | Series C | 5089 |
Acquired companies in CD-Venture's Portfolio
4 companies from CD-Venture's portfolio have been acquired. The most recent acquisition was Stocard in Jul 2021 by Klarna for $*****.Here are CD-Venture's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 23, 2021 | Dec 11, 2012 | Seed | 4789 | |
Sep 04, 2019 | May 17, 2011 | Series A | 1816 | |
Aug 08, 2018 | Mar 10, 2015 | Series C | 7840 | |
Jun 25, 2018 | Sep 15, 2015 | Series B | 9157 |
Team profile of CD-Venture
CD-Venture has a team of 2 members including 2 Partners located in Germany. CD-Venture's team does not sit on the board of any company as of now.Co-investors of CD-Venture
Over the past 16 years, 109 investors have co-invested in CD-Venture's portfolio companies. This includes funds and angels.
- Invested before CD-Venture: NGN Capital, Kfw and 40 others have invested in rounds before CD-Venture. There are 2 companies where NGN Capital has invested before CD-Venture and 2 companies where Kfw has invested before CD-Venture.
- Top Co-investors of CD-Venture: 29 investors entered a company along with CD-Venture. These include investors like Yabeo (1 company).
- Invested after CD-Venture: A total of 38 investors have invested in CD-Venture's portfolio after their investments. Top Investors include Boehringer Ingelheim (1 company), DaVita Venture Group (1 company) and Rock Health (1 company).
Recent News related to CD-Venture
•
Wellth Secures $36M to Expand AI-Powered Behavior Change PlatformHIT Consultant•Aug 22, 2025•Mercato Partners, FCA Venture Partners, Comcast Ventures, Wellth and 3 others
•
Germany’s charging infrastructure provider Wirelane acquires On Charge; raises €11MSilicon Canals•Aug 24, 2023•Wirelane, On Charge, CD-Venture
•
Health tech startup Wellth fetches $20m Series BVCJ•Mar 30, 2023•Yabeo, Wellth, SignalFire, Partnership Fund for New York City and 7 others
•
Bayern Kapital, CD-Venture in series-C for TriOptoTecUnquote•Apr 21, 2020•CD-Venture, Bayern Kapital, dyphox
•
Leon inks Series BVCJ•Apr 16, 2020•Leon-nanodrugs, BayBG, Evotec, Eckenstein-Geigy-Foundation and 3 others
•
Fresh capital for Munich nanotechnology start-upVenture Capital magazine•Apr 16, 2020•BayBG, Evotec, Leon-nanodrugs, TVM Capital Life Science and 4 others
•
Behavioral economics startup Wellth lands $5.1MMobiHealthNews•Sep 13, 2018•Wellth, Boehringer Ingelheim Venture Fund, NFP, CD-Venture and 5 others
•
Machine Learning Healthcare Startups Get $10M In Seed FundingPYMNTS.com•Jun 04, 2018•Bessemer Venture Partners, Allena, HBM Partners, Frazier Healthcare Partners and 23 others
•
Massachusetts' Exosome Diagnostics Snags $30 Million | BioSpaceBioSpace•Jul 24, 2017•Exosome Diagnostics, Forbion, Tiger Advisors, Blue Ridge Capital and 4 others
•
stocard - ein stiller, aber erfolgreicher App-Platzhirsch - deutsche-startups.dedeutsche-startups.de•Mar 18, 2016•Stocard, Shortcut Ventures, Alstin, CEWE and 3 others
